Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Retained Earnings (2020 - 2025)

Foghorn Therapeutics has reported Retained Earnings over the past 6 years, most recently at $24000.0 for Q4 2025.

  • Quarterly results put Retained Earnings at $24000.0 for Q4 2025, up 100.0% from a year ago — trailing twelve months through Dec 2025 was $24000.0 (up 100.0% YoY), and the annual figure for FY2025 was $24000.0, up 100.0%.
  • Retained Earnings for Q4 2025 was $24000.0 at Foghorn Therapeutics, up from -$610.8 million in the prior quarter.
  • Over the last five years, Retained Earnings for FHTX hit a ceiling of $24000.0 in Q4 2025 and a floor of -$610.8 million in Q3 2025.
  • Median Retained Earnings over the past 5 years was -$94.4 million (2021), compared with a mean of -$209.7 million.
  • Biggest five-year swings in Retained Earnings: plummeted 3731280.0% in 2022 and later soared 102.82% in 2025.
  • Foghorn Therapeutics' Retained Earnings stood at -$10000.0 in 2021, then plummeted by 3731280.0% to -$373.1 million in 2022, then soared by 99.78% to -$826000.0 in 2023, then plummeted by 67476.76% to -$558.2 million in 2024, then soared by 100.0% to $24000.0 in 2025.
  • The last three reported values for Retained Earnings were $24000.0 (Q4 2025), -$610.8 million (Q3 2025), and -$44000.0 (Q2 2025) per Business Quant data.